Inflammatix secures $7.4M in BARDA funding

By staff writers

October 29, 2020 -- Molecular diagnostics firm Inflammatix has secured an additional $7.4 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) to support the development of its ViraBac EZ acute infection test.

The funding will allow the company to further develop its point-of-care test for diagnosing infection and is part of a larger BARDA contract worth up to $72 million if milestones are met, the company said.

Inflammatix's ViraBac EZ test uses a blood sample to identify gene expression patterns in the immune system and to determine whether an infection is bacterial or viral, the company said; it is used with the firm's Myrna test system, which reads RNA using machine learning and delivers results in less than 30 minutes.

BARDA is part of the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response.

Inflammatix gets $32M infusion for HostDx rapid POC tests
California startup Inflammatix has raised $32 million in series C financing, which it plans to use to move its HostDx rapid point-of-care (POC) tests...
Inflammatix scores BARDA contract for infection tests
Startup Inflammatix is set to get $6 million from the U.S. Biomedical Advanced Research and Development Authority (BARDA) and up to $72 million...
AACC: Inflammatix sepsis test wins Disruptive Technology contest
ANAHEIM, CA - A blood test for sepsis developed by California startup Inflammatix beat out products from two other companies to win the Disruptive Technology...

Copyright © 2020

Last Updated ls 10/29/2020 11:00:36 AM